![People working in lab](/%5E%5Ecdi={43513A8D-0012-473A-A5A1-570018B04076}%5Ehash=/-/media/project/qiagen/qiagen-home/content-worlds/ngs/s_1321_5_cc_gen_gi463245525.jpg)
Unraveling the mutational landscape of myeloid neoplasms
Myeloid neoplasms are a group of diseases characterized by a wide range of mutations across multiple genes, including oncogenes and tumor suppressor genes. These genes include CALR and CEBPA for acute myeloid leukemia (AML) and TP53 or RB1 for chronic myeloid leukemia (CML). Targeted NGS has the potential to reveal the mutational landscape of myeloid neoplasms comprehensively. But everything hinges on choosing the right panel. Low allele frequency of variants, high GC content, low enrichment of target DNA and ultra-long workflows can delay insights. Skip the drama and detect low-frequency variants with high confidence. Our QIAseq Targeted DNA Pro Panel for myeloid neoplasms has been developed with your challenges in mind.
Top 5 reasons why you should upgrade to the QIAseq Targeted DNA Pro Human Myeloid Neoplasms Focus Panel:
![Dr Barnaby Clark](/%5Ecx=0%5Ecy=0%5Ecdi={B4D1002F-6FAD-46F0-B8DA-9AB2A6D026EF}%5Ehash=B7FB76F74EEBE553BB188546BF2DA196/-/media/project/qiagen/qiagen-home/content-worlds/ngs/s_1252_4_ls_gg_genomics_barnaby_clark_2_16x9.jpg)
「QIAseq Targeted DNA Proのライブラリー調製のハンズオン時間は約6時間に短縮されるので、1日でライブラリー調製が可能となります。これは、ターンアラウンドタイムが短いがん研究ラボにとって非常に魅力的です。」
Kings College Hospital NHS Foundation Trust、精密医療研究所長、Dr. Barnaby Clark